US 9168266
Hybrid diazeniumdiolated compounds, pharmaceutical compositions, and method of treating cancer
granted A61KA61K31/655A61K31/69
Quick answer
US patent 9168266 (Hybrid diazeniumdiolated compounds, pharmaceutical compositions, and method of treating cancer) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Oct 22 2035 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- The United States of America, as represented by the Secretary, Department of Health and Human Services
- Grant date
- Tue Oct 27 2015 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Oct 22 2035 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 23
- CPC classes
- A61K, A61K31/655, A61K31/69, A61K31/704, A61K45/06